Caxton Corp
- SEC CIK
- 0001388551
- Latest filing
- Aug 13, 2026
Holdings in Q4 2025
Holdings as of Dec 31, 2025, filed Feb 13, 2026. Long positions only; changes compare share counts with Q3 2025.
- Positions
- 11
- −1 vs. Q3 2025
- Portfolio value
- $4.28M
- −$18.6M (−81.3%) vs. Q3 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GLDSPDR Gold Trust | ETF | 6,964 | $2.76M | 64.5% | −322−4.4% | Reduced | History |
| BRK.BBerkshire Hathaway Inc | Stock | 710 | $356.8K | 8.3% | +59+9.1% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 8,919 | $292.2K | 6.8% | +8,919 | New | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 15,688 | $210.1K | 4.9% | −11,323−41.9% | Reduced | History |
| KYTXKyverna Therapeutics, Inc. | COM | 18,773 | $176.5K | 4.1% | −4,208−18.3% | Reduced | History |
| CMPXCompass Therapeutics, Inc. | COM | 29,495 | $158.4K | 3.7% | −24,008−44.9% | Reduced | History |
| LXEOLexeo Therapeutics, Inc. | COM | 13,943 | $138.5K | 3.2% | −3,389−19.6% | Reduced | History |
| XFORX4 Pharmaceuticals, Inc | COM NEW | 15,557 | $62.2K | 1.5% | +15,557 | New | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 28,453 | $58.3K | 1.4% | +12,060+73.6% | Added | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 10,527 | $39.4K | 0.9% | −408−3.7% | Reduced | History |
| CNTXContext Therapeutics Inc. | COM | 18,403 | $27.1K | 0.6% | 00.0% | Unchanged | History |
Sold out since Q3 2025 (3)
Positions held at the end of Q3 2025 that are gone from this filing.